Allos Therapeutics Inc

Allos Therapeutics — Merger or Acquisition (September 2011)

20 slides from Allos Therapeutics's merger presentation, Sep 19, 2011

  1. Slide 1: AMAG Pharmaceuticals, Inc. Fall 2011

    AMAG Pharmaceuticals, Inc. FALL 2011 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, our s

  3. Slide 3: Important Merger Information and Where to Find It

    Important Merger Information and Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. The proposed merger between AMAG and Allos will be submitted to the re

  4. Slide 4: Lead Product Feraheme (ferumoxytol)

    Lead Product Feraheme® (ferumoxytol) Injection for intravenous (IV) use; approved in US in 2009 as an IV iron replacement therapy for adult chronic kidney disease (CKD) patients with iron deficiency anemia (IDA) CKD marketing applications under review in EU, Canada and Switzerland; decisions for Can

  5. Slide 5: 2Q 2011 Financials (unaudited) and Proposed Merger with Allos

    2Q 2011 Financials (unaudited) 2Q 2011 total revenues of $15.4 million, including Feraheme net product revenues of $12.8 million 2Q 2011 total operating costs and expenses of $35.6 million Cash and investments of $264 million as of 6/30/11; no debt Proposed Merger with Allos Therapeutics Signed defi

  6. Slide 6: Feraheme has a Favorable Dosing Regimen

    Dosing1 Feraheme Other IV Irons Schedule 2 x 510 mg 5-10 x 100–200 mg Delivery 17-second IV injection Slow push or 15-60 minute infusion Observation Period 30 minutes post dosing2 30 minutes post dosing2 Regimen (1 g) 2 treatments within one week 5-10 treatments within one month Feraheme has a Favor

  7. Slide 7: Attractive Opportunity in the Non-Dialysis Dependent CKD IDA Market

    7 Attractive Opportunity in the Non-Dialysis Dependent CKD IDA Market US Census U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kid

  8. Slide 8: Existing Market Segments: A Large and Growing Opportunity in Non-Dialysis CKD

    Existing Market Segments: A Large and Growing Opportunity in Non-Dialysis CKD AMAG estimates that ~50% of IV iron grams used in US outside of dialysis is for the treatment of CKD patients. 50% of which represents ~$200 million Feraheme CKD Market Opportunity (assuming $500/gram) 8

  9. Slide 9: 24% Growth Quarter-over-Quarter in 2Q 2011 Non-Dialysis CKD Provider Demand

    24% Growth Quarter-over-Quarter in 2Q 2011 Non-Dialysis CKD Provider Demand Feraheme Grams 9 Non-dialysis Market Share (percent) Sources: IMS Health Monthly DDD derived grams

  10. Slide 10: Iron Deficiency Anemia (IDA) Opportunity

    Iron Deficiency Anemia (IDA) Opportunity 10 Estimated opportunity is nearly 4.5 million patients 5% are treated with IV iron Increasing IV iron treatment rates could dramatically expand the market opportunity Iron dextrans are the only IV irons with a broad IDA label Our market research indicates ph

  11. Slide 11: 2Q 2011 Summary

    2Q 2011 Summary Provider demand increased 24% quarter-over-quarter Momentum building in hematology/oncology clinics and hospitals – high-volume sites of care where non-dialysis CKD patients receive IV iron (2Q market shares: 23% hem/onc, 6% hospitals, 42% nephrology) Label changes to Feraheme, Venof

  12. Slide 12: Merger with Allos

    MERGER with ALLOS 12

  13. Slide 13: Merger Highlights

    Merger Highlights 13 Terms Stock for stock transaction Allos stockholders will receive 0.1282 AMAG shares for each Allos share held Ownership at Closing AMAG 61% / Allos 39% 2010 Product Revenues Feraheme 2010 net product revenues: $59.3 million Folotyn 2010 net product revenues: $35.2 million Cash

  14. Slide 14: Strategic Rationale of Merger

    Strategic Rationale of Merger Fits with long-term strategy of building a profitable specialty pharmaceutical company in area of high strategic interest (hematology/oncology) Overlapping call points in hematology/oncology and hospitals provides enhanced access for Feraheme Largest non-dialysis CKD ma

  15. Slide 15: NewCo Financial Rationale

    NewCo Financial Rationale Conservative combined net product revenues in 2013 of at least $125 million Assuming current US labels/indications for Folotyn and Feraheme, and EU and Canadian approval for Feraheme for CKD NewCo cash operating expenses in 2013 expected to be no greater than $120 million (

  16. Slide 16: Potential Financial Upside

    Potential Financial Upside Revenues Feraheme CKD and Folotyn revenue synergies through expanded share of voice and access Feraheme sales from US IDA approval/launch Folotyn sales from label expansions (first-line PTCL and rrCTCL) Folotyn use derived from results of investigator sponsored research Ro

  17. Slide 17: Multiple Milestones Provide Future Growth Opportunities

    Multiple Milestones Provide Future Growth Opportunities 2011 Milestones Feraheme Second source manufacturing approved Decision expected regarding Canadian regulatory application for IDA in CKD Folotyn Initiate Phase 3 study in first line PTCL; SPA agreement with FDA in place – first patient enrolled

  18. Slide 18: Focused on Building Long-term Value for Shareholders

    Focused on Building Long-term Value for Shareholders We believe the merger with Allos Therapeutics Expands access to hematology/oncology for Feraheme in CKD and broad IDA indications Leverages existing commercial infrastructure and cost-base in hematology/oncology space Spreads public company costs

  19. Slide 19: Backup Slide

    Backup Slide INVESTOR CONTACT: 617-498-3361 19

  20. Slide 20: Feraheme and Folotyn Overview

    FERAHEME FOLOTYN Description Therapeutic iron formulation delivered via intravenous (IV) injection U.S. approval June 2009 Folate analogue metabolic inhibitor delivered via intravenous (IV) injection U.S. approval September 2009 Labeled Indication Approved for the treatment of iron deficiency anemia

Allos Therapeutics — Merger or Acquisition (September 2011) on 6ix